Skip to main content

Advertisement

Table 2 Summary of the HGF promoter sequencing

From: Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients

Patient no. SNP (NCBI dbSNP) INDEL mutation NCBI dbSNP DATE length Sequence region HGF Serum levels
MM 4 −1652C/T Rs3735520 27 −2920 – +120 High
MM 5 −2142C/A Rs11763015 26 −2870 – +120 High
−1652C/T Rs3735520
MM 7 −2142C/A Rs11763015 22 −2910 – -20 High
−1652C/T Rs3735520
MM 14 2309 T/A* Rs149178895* 29 −2920 – +120 High
−1652C/T Rs3735520
MM 22   15 −2280 – +120 High
MM 24 Rs3735520 28 −2870 – +120 High
−1652C/T
MM 29 −1652C/T Rs3735520 27 −2870 – +120 High
MM 3 −1652C/T Rs3735520 22 −2870 – +120 Low
MM 12 −2142C/A Rs11763015 22 −2840 – -1710 Low
MM 16 −1652C/T Rs3735520 23 −2810 – +120 Low
MM 17 −1652C/T Rs3735520 26 −2730 – +120 Low
MM 23 −2142C/A Rs11763015 25 −2870 – +120 Low
  −1652C/T   Rs3735520    
  1. Genomic DNA isolates from CD138+ cells were used to amplify segments of the HGF promoter. PCR products were pre-treated with exonuclease I and shrimp alkaline phosphatase and directly used for Sanger DNA sequencing. RefSeq gene NG_016274 was used as reference sequence. SNP and sequence region are relative to transcription start site.
  2. SNP positions Rs3735520 and Rs11763015 are depicted relative to transcription start site (NM_000601.4:c).
  3. *SNP position RS149178895 is depicted relative to gene region NG_016274.1.